ACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $45.04 Million

Wall Street brokerages predict that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will announce sales of $45.04 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for ACADIA Pharmaceuticals’ earnings. The lowest sales estimate is $44.43 million and the highest is $45.60 million. ACADIA Pharmaceuticals posted sales of $11.96 million during the same quarter last year, which suggests a positive year-over-year growth rate of 276.6%. The company is expected to report its next quarterly earnings report on Tuesday, February 27th.

On average, analysts expect that ACADIA Pharmaceuticals will report full year sales of $45.04 million for the current financial year, with estimates ranging from $125.77 million to $126.90 million. For the next financial year, analysts forecast that the company will report sales of $247.03 million per share, with estimates ranging from $210.60 million to $270.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.10. The company had revenue of $35.58 million for the quarter, compared to the consensus estimate of $32.03 million. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. ACADIA Pharmaceuticals’s quarterly revenue was up 571.3% on a year-over-year basis. During the same period last year, the business posted ($0.61) EPS.

Several research analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, November 8th. J P Morgan Chase & Co set a $50.00 price objective on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 5th. Piper Jaffray Companies restated a “buy” rating and set a $61.00 price objective (up from $54.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, October 5th. JMP Securities raised their price objective on ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, October 5th. Finally, ValuEngine upgraded ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $47.44.

ACADIA Pharmaceuticals (ACAD) traded down $0.09 on Monday, reaching $30.16. The company’s stock had a trading volume of 1,813,600 shares, compared to its average volume of 1,661,695. ACADIA Pharmaceuticals has a one year low of $24.31 and a one year high of $41.20.

In other news, EVP Glenn Baity sold 37,500 shares of ACADIA Pharmaceuticals stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $40.91, for a total value of $1,534,125.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 22.25% of the company’s stock.

Several institutional investors have recently bought and sold shares of ACAD. San Francisco Sentry Investment Group CA acquired a new stake in shares of ACADIA Pharmaceuticals in the 2nd quarter worth $125,000. Oppenheimer Asset Management Inc. boosted its position in shares of ACADIA Pharmaceuticals by 10.0% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 468 shares in the last quarter. Turner Investments LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter worth $188,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ACADIA Pharmaceuticals by 43.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,670 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 1,710 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its position in shares of ACADIA Pharmaceuticals by 56.8% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,509 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 2,358 shares in the last quarter. 93.89% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “ACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $45.04 Million” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://sportsperspectives.com/2017/12/04/acadia-pharmaceuticals-inc-acad-expected-to-announce-quarterly-sales-of-45-04-million.html.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply